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Abstract: Obesity prevalence continues to be a foremost health concern across the globe leading to
the development of major health risk conditions like type II diabetes, hyperlipidemia, hypertension
and even cancers. Because of the deprived drug-based management system, there is an urgent
need for the development of new drugs aiming at satiety and appetite control targets. Among the
reported satiety signaling targets, 5HT2C receptor plays a crucial role in decreasing appetite and has
become a promising target for the development of anti-obesity drugs. Lorcaserin, a 5HT2C receptor
agonist and the only drug available in the market, was designed based on the receptor mechanism of
action. Due to limited drug options available and considering the adverse drug effects of Lorcaserin,
the development of new drugs which are highly specific toward the 5HT2C target and with lesser
side effects is essential. The present study is majorly focused on developing new 5HT2C agonists
through computational approaches like screening, docking, and simulation using Phase, QikProp,
Glide and Desmond applications of the Schrodinger suite. Screening protocols resulted in eight best
hit molecules with affinity for the receptor and among them, five hits displayed binding affinity
toward the conserved residue Asp 134 of the receptor. The stability of the five molecules in complex
with the 5HT2C receptor was studied through molecular dynamic simulations. Three molecules,
ZINC32123870, ZINC40312983 and ZINC32124535, maintained stable interactions with the Asp 134
residue throughout the 50 ns simulation run time. Further, due to the high sequence similarity
seen among the receptors of 5HT2 family, the three potential hits were cross validated against other
subtypes 5HT2A and 5HT2B of the 5HT2 family to determine the specificity of the molecules against
the target. Among the three hits, ZINC32124535 was identified as the best potential hit based on
the hydrogen bond interaction percentage with Asp residue [5HT2A (Asp 155:60%); 5HT2B (Asp155:
No interaction); 5HT2C (Asp 134:86%)]. The ZINC32124535 molecule produced one salt bridge and
hydrogen bond interactions with Asp 134, alike the known drug Lorcaserin. Based on the results,
ZINC32124535 was identified as the best potential hit against the 5HT2C receptor.
Keywords: 5HT2C receptor; ZINC natural molecule database; pharmacophore modeling; glide;
dynamic simulations
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1. Introduction
Obesity, an important threat to global public health in terms of prevalence and economic burden,
demands a wide range of interventions from prevention to advance treatments. Obesity is primarily
a condition involving excessive fat accumulation in the body and is associated with various health
problems like developing type II diabetes, dyslipidaemia, fatty liver disease, osteoarthritis, coronary
heart disease, hypertension, coronary artery disease and even cancers [1–3]. So far, several targets related
to the central nervous system (CNS) like 5HT2C, NPY (NeuropeptideY), and AgRP (Agouti-related
protein) etc., and the non-central nervous system like pancreatic lipase, leptin, ghrelin etc., [4,5] were
reported as obesity targets. However, only pancreatic lipase (inhibitor) and 5HT2C receptor agonists
have gained importance in drug discovery compared to the other targets. To date, there are six Food
and Drug Administration (FDA)-approved drugs available in the market. Among them, Orlistat
(pancreatic lipase inhibitor) and Lorcaserin (5HT2C receptor agonist) widely persisted with a weight
loss of 3.0% and 3.0–3.6% per year, respectively, compared to placebo [6,7].
The present study is mainly focused on the 5HT2C receptor, one of the obesity neuroreceptor
targets mainly involved in satiety. The 5HT2C receptor belongs to the 5HT2 family (serotonin), which is
highly expressed in the central nervous system and targeted in multiple disorders such as obesity, eating
disorders, depression, anxiety, obsessive-compulsive disorder, chronic pains, epilepsy, and erectile
dysfunction [8–18]. The 5HT2 receptor family was further classified into three subtypes, namely
5HT2A, 5HT2B and 5HT2C with high sequence similarity, playing crucial roles in signal transduction
pathways [19]. Due to the high sequence similarity within the subtypes, it has been a challenge to
design drugs specifically targeting the 5HT2C receptor.
Neural signaling related to food intake is controlled by ventromedial nucleus of hypothalamus
(satiety center) and lateral hypothalamus (hunger center). The intake of food is simulated by
agouti-related protein and neuropeptide Y, known as the stimulatory group, whereas cocaine and
amphetamine-regulated transcript (CART) and pro-opiomelanocortin (POMC) neurons are considered
as supressors of food intake [20]. The activation of 5HT2C neurons of anorexigenic POMC activates the
release of alpha-melanocyte-stimulating hormone (α-MSH). α-MSH further acts on the Melanocortin 4
receptor (MC4R) present in the para ventricular nucleus of hypothalamus, which promotes decrease in
appetite [21]. Hence, the 5HT2C receptor is considered to be a potent obesity target [22].
Lorcaserin ([1R]-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine) is a known FDA-approved
5HT2C receptor agonist [23] aimed to treat obesity by reducing hunger craving and suppressing
appetite [24]. Many side effects like cardiovascular problems, nausea, vomiting, constipation, diarrhea,
fatigue, upper respiratory tract infection, urinary tract infections, back pain, headache, dizziness and rash
were reported by Lorcaserin usage [25,26]. Overall, the usage of this drug had minimal effects on body
weight but had many side effects. Hence, there is a need to develop new generation drugs which can act
specifically with lowered side effects. The current study analyzed pharmacophore-based screening of
natural molecules targeted toward the 5HT2C receptor and validated them against other subtypes for
specificity via docking and molecular dynamic simulation studies.
2. Materials and Methods
2.1. Pharmacophore Hypotheses Generation and Screening
2.1.1. Dataset Preparation
A total of 69 agonists from previous studies along with their known activity were considered in the
development of the pharmacophore model [27]. All the molecules were sketched using the Chembio
draw tool imported to Maestro. LigPrep module was used to prepare the molecules by applying
OPLS_2005 force field at pH 7, followed by conformer generation using ConfGen of Macro-Model
module with thorough sampling.
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2.1.2. Pharmacophore Hypotheses Generation and Validation
The pharmacophore modeling was performed using the PHASE module of Schrodinger suite [28].
The PHASE module develops the pharmacophore hypotheses from multiple ligands. The skeleton
of pharmacophore involved six features: Hydrogen bond donor (D), hydrogen bond acceptor (A),
hydrophobic region (H), negatively charged region (N), positively charged region (P), and aromatic
rings (R). With the scoring parameters, the hypotheses were ranked based on the alignment against
the active dataset. In addition, the quality of the hypothesis was assessed using parameters such as
survival score, sites, vector, and selectivity scores. In this protocol, four out of five pharmacophore
features were chosen as must match and other features with default settings. The hypothesis validation
application from the PHASE module of Schrodinger suite was used to validate the hypotheses.
To run the application, the active dataset and a decoy set were needed. The decoy set, comprising
of 1000 molecules with a molecular weight of 360, was employed. The pharmacophore hypothesis
validation was confirmed based on the number of actives retrieved from active dataset, percentage of
actives resulted from decoy set and enrichment factor (EF).
2.1.3. Screening of the ZINC Database
The ZINC natural compound database, containing nearly 140,311 compounds, was used in
screening the agonists for the 5HT2C receptor. These molecules were initially minimized using the
Canvas 3D minimization tool from Schrodinger suite. The minimized natural molecule database
was screened using advanced pharmacophore screening of the PHASE module [28] with validated
pharmacophore hypotheses and hits acquired were ranked based on their fitness scores.
2.2. ADME Screening and PAINS
Drug-likeness of the hits obtained from the above screening filter was predicted by QikProp
assessing pharmacological properties such as CNS, QPlogBB and Lipinski’s rule-of-five descriptors [29].
The central nervous system (CNS) property predicts the efficiency of the molecule in the central
nervous system and ranges between +2 (active) and −2 (inactive). The predicted brain/blood
(QPlogBB) range of −3.0 to 1.2 predicts the ability of the molecule to cross the blood brain barrier.
The Lipinski’s rule-of-five property was used: Hydrogen bond donor≤ 5, hydrogen bond acceptor ≤ 10,
QPlogPo/w ≤ 5, molecular weight < 500 KDa. Compounds satisfying these properties were considered
as drug–like compounds. The filtered molecules were further studied using ligand docking studies.
A pan-assay interference compounds (PAINS) filter was also implied over screened molecules to
remove false positives [30].
2.3. Receptors Preparation
Prior to the docking studies, 5HT2 family member’s 5HT2A, 5HT2B, and 5HT2C receptors were
prepared. For 5HT2B and 5HT2C, crystal structures were available, whereas the 5HT2A crystal structure
was not available. Hence, to elucidate the 5HT2A three-dimensional structure, Prime homology
modeling application was opted. The 5HT2C receptor crystal structure (PDB ID: 6BQG) was chosen as
a template to build the 5HT2A homology model. The first step involved in the homology modeling
was sequence retrieval from the Uniprot database (ID: 28223) in FASTA format and importing
into the modeling tool. Further, Protein Specific Iterated (PSI) BLAST algorithm (integrated in the
application) [31] was performed against Protein Data Bank (PDB) [32] to identify the homologous
protein structures and the template was selected based on the sequence similarity. Target and the
template sequences were aligned using the ClustalW embedded in the module. Further, through
SSpro program bundled in the application, the secondary structure of the receptor was predicted.
Crystal protein conjugated ligands were not included during the structure modeling. In a similar way,
the 5HT2C homology model was also built, choosing the protein sequence (UniProtKB - P28335) and
template PDB ID: 4NC3 for comparative study with the crystal structure. The crystal and modeled
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receptors were refined before proceeding to docking studies. The protein preparation wizard tool was
used to refine the receptor and parameters used in refining the receptors were, adding hydrogens;
creating disulphide bonds, zero order bonds, and metal atoms; converting any selenomethionines to
methionines and desolvation by removing crystallized free water molecules beyond the 5 Å distance
from the ligand [33]. Further, the hydrogen bonds in the receptor were optimized to repair overlapping
hydrogens. Finally, force field OPLS_2005 was applied to minimize the receptor [34].
2.4. Ligand Docking Studies
Ligand docking was performed using the GLIDE module, following grid-based docking protocol.
Once the binding site was analyzed, the receptor continued to generate a grid around the predicted
active site to lock active amino acids inside the grid (Grid box size (x, y, z coordinates): Grid-center:
38.63, 31.17, 56.86; Inner-box: 10, 10, 10; and Outer-box: 27.39, 27.39, 27.39). Finally, hits were
obtained after absorption, distribution, metabolism and excretion (ADME) filters and docked against
the predicted active site of the modeled receptor using the Glide XP docking protocol [35]. The major
settings involved in the docking studies were adding the receptors grid file in the receptor grid box,
prepared ligands in the ligands tab, keeping precision to XP (extra precision) in the setting tab and
returning all tab parameters to default. Based on the G-scores, molecules were tabulated.
2.5. Binding Free Energy Calculations Using Prime/MM-GBSA
Prime/MM-GBSA was employed to calculate the binding free energies of docked complexes.
The pose viewer file of docked complexes with OPLS-AA force field in VSGB solvent model was used
to calculate energies. Using the following equation, free energy of the complexes was calculated.
MMGBSA dG Bind = EComplex − EReceptor − ELigand (1)
where MMGBSA represents molecular mechanics energies combined with the generalized Born and
surface area continuum solvation, dGbind represents the calculated relative free energy of both the
ligand and receptor strain energy, Ecomplex represents the MM/GBSA energy of the minimized complex,
Ereceptor represents the mean MM/GBSA energy of protein (unbound, minimized) without ligand,
and Eligand represents the MM/GBSA energy of the ligand after removing it from the complex [36].
2.6. Molecular Dynamics Simulations
The 5HT2C receptors in complex with the lead molecules were further refined by molecular
dynamic simulations (MDS) using Desmond software [37,38] and their interaction consistency was
studied. Initially, using the system builder application of desmond module, the modeled receptor
was inserted into the pre-equilibrated palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) bilayer
with default parameters and solvated with SPC (simple point-charge) water model in an orthorhombic
periodic boundary box (Box size; distances (Å): a:10 × b:10 × c:10 and Angles: α:900 × β:900 × γ:900).
To neutralize the system, Cl− ions were added depending on total charge of model along with
0.15 M salt concentration. The next step was minimizing the model obtained from the system builder
by setting the maximum iterations to 2000. The remaining parameters were set to default in the
minimization application. Finally, dynamic simulations were carried with the minimized model
in NPT (isothermal–isobaric ensemble, Number of particles (N), Pressure (P) and Temperature (T))
ensemble, 300 K temperature and 1 bar pressure, relaxed using molecular dynamics application of the
Desmond module. The molecular dynamic simulations (general sampling method) job was carried
out for a period of 50 ns. From the obtained trajectory file, root-mean-square deviation (RMSD),
root-mean-square fluctuation (RMSF) and H-bond interactions of the complex were analyzed. During
simulations, especially in the RMSF graph generation, the amino acid numbers were shifted, i.e.,
the crystal structure residue number 46 was shown at first position. The residue numbering is presented
accordingly in all the RMSF results.
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3. Results and Discussion
3.1. Pharmacophore Modeling and Validations
The ligand based pharmacophore design was based on known actives possessing pharmacological
activity over the selected target. The pharmacophore model was developed by considering 69 agonists
with known IC50 values as a dataset [27,39]. IC50 values of the selected molecules were converted to
pIC50 and further dataset was divided into two groups, training and test sets, respectively. Twenty-two
molecules with pIC50 > 3.5 were considered as a training set for the generation of pharmacophore
models and the remaining molecules were considered as a test set. By keeping the maximum and
minimum number of sites option to four in pharmacophore hypothesis application settings, a total
of six hypotheses with altered variant combinations were generated. Based on survival score and
superior alignment with actives, the best top hypothesis AADHR was selected. The scoring function,
which was employed to rank generated variants, was determined based on the number of sites and
ligands matched, vector size, selectivity, and volume size, which would further help in the selection of
the hypothesis rationally.
The five sites hypothesis AADHR revealed highest survival score of 5.143 (Table 1) comprising of
two hydrogen bond acceptors (A), one donor (D), one hydrophobic group (H) and a ring aromatic (R)
feature. The hypothesis and its alignment against molecule in the actives dataset were depicted in the
Figure 1. The hypothesis showed an EF of 44, the count and percentage of actives in the top 20% of the
decoy results was 82.6%, respectively. The scores represent pharmacophore hypothesis competence,
adequacy and capability of screening best number of actives from database.
Table 1. Hypothesis generated through PHASE run.
Hypothesis ID No. of Sites SurvivalScore Site Score Vector Score
Volume
Score Selectivity
AADHR
5
5.143 0.766 0.825 0.622 1.515
AAADH 4.909 0.688 0.769 0.517 1.214
AAAH
4
5.064 0.957 0.994 0.650 1.015
AAHR 5.171 0.860 0.972 0.631 1.217
DHRR 5.090 0.660 0.934 0.592 1.490
ADHR 4.939 0.737 0.919 0.581 1.287
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3.2. Screening of the ZINC Natural Molecule Database
Advanced pharmacophore screening of phase module was used for screening the built and
minimized 3D ZINC natural database. The database was screened with generated hypothesis by
retaining default parameters except for matching tab, which was set to five out of five. Using the
fitness score >1.0, the top-listed 1000 hits were taken into account and progressed to ADME analysis
using QikProp application. Eight ligand molecules resulted as best hits based on CNS activity with
+2, followed by zero violation of the Lipinski’s rule of five and good QPlogBB range in addition to
approved PAINS filter (Table 2). Eight ligand molecules were carried forward to docking studies to
analyze their binding affinity with the 5HT2C receptor.
Table 2. Docking scores of potential hits and their pharmacological properties.
Core Moiety
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3.3. Receptor-Ligand Docking Studies (5HT2C)
Receptor downloaded from protein databank was prepared using the protein preparation wizard
to convert the raw structure into a refined structure [40,41]. Through a receptor grid generation step,
the prepared protein active site was locked and docked with seven out of eight ligand compounds
selected from the above steps. ZINC40312983 and ZINC40312987 were isomers and, hence, only
ZINC40312983 was considered for docking studies using the Glide XP docking protocol. Along with
seven hits, the standard agonist drug Lorcaserin was also added to the docking list for comparative
analysis and their docking G-scores were found ranging between −9.58 to −6.26 (Table 2). Based on
the molecules hydrogen bond interactions with the conserved amino acid Asp 134 of the receptor, five
ligand molecules were selected and their interaction profiles along with Lorcaserin were studied.
The known drug Lorcaserin maintained three interactions, namely one hydrogen bond (NH2+
with =O of Asp 134 residue), one salt bridge (NH2+ with the oxygen atom of Asp 134 residue), and
one pi–pi interaction with Phe 327 residue, in the active site of the receptor (Supplementary Figure S1).
The receptor–ZINC32123870 in complex form was sustained by two pi–pi stackings, one hydrogen
bond and a salt bridge. One hydrogen bond was formed between a NH+ group of ZINC32123870
with the oxygen atom of important amino acid residue Asp 134 of the receptor and salt bridge was
also perceived with the same amino acid. Among two pi–pi interactions, one was maintained between
Phe 327 of receptor with an aromatic group of main moiety and another one was found between Phe
328 and aromatic ring present in the R-group of ligand Figure 2a. ZINC32124535 made one hydrogen
bond and one salt bridge with receptor by the end of the docking studies. The two interactions were
shared between the oxygen atom of Asp 134 and NH+ of ligand (main moiety), as seen in Figure 2b.
The binding affinity between receptor-ZINC40312983 complex (Figure 2c) was attributed to one salt
bridge and two hydrogen bonds. The interactions of the molecule with receptor are as follows: Oxygen
atom of Asp 134 and NH+ of ZINC40312983 molecule (salt bridge), NH+ (main moiety) of the molecule
with Asn 331(=O) and =O attached to the sulphur atom in the molecule with NH group of the Leu 209
(hydrogen bonds).
Receptor and ZINC32123898 complex was maintained through a salt bridge and two pi–pi
interactions. The salt bridge was formed between ligand (main moiety NH+ group) and oxygen atom
of Asp 134 amino acid of the receptor. Two stackings were observed with the Phe 328 residue: One
with a five-membered ring and another with a six-membered ring of main moiety. The docking studies
of receptor and ZINC32123782 complex revealed one hydrogen bond (NH+) and one salt bridge (NH+)
interaction with Asp 134. Along with them, three pi–pi interactions occurred, one with Phe 328 second
Trp 324 with aromatic ring present in the R-group of ligand and the third pi–pi interaction was shared
between aromatic ring (main moiety) of ligand with Phe 327.
The interaction of the highly conserved residue Asp 134 with molecules was considered the
most important in performing agonist activity [27,39,41,42]. The other important amino acids in the
vicinity region reported were Ser 138, Tyr 358, Tyr 324, and Arg 195 [43,44]. The standard drug and
five screened hits showed interactions with these important amino acids in the active site vicinity.
The important residue Asp 134 was found to maintain an interaction with the NH+ group of the
compounds either through hydrogen bond or salt bridge. Among these five compounds, three
compounds (ZINC32123870, ZINC40312983 and ZINC32124535) individually produced one hydrogen
bond and one salt bridge. The rest of the two established only one salt bridge with Asp 134. These
interactions resulted because the NH+ group of compounds protruded toward Asp 134 residue during
docking and thereby attained a stable confirmation inside active site. In addition, the attractive
forces of negatively charged Asp residue and positively charged NH+ group of hits assisted them to
accommodate well inside active site pocket by forming a stable complex.
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3.4. Dynamic Simulations of the 5HT2C-Ligand Complexes
Based on docking studies, five ligand molecules were found to produce interactions with active
site amino acids. To verify steadiness of these interactions, the 5HT2C-ligand complexes were further
subjected to molecular dynamic simulations for a period of 50 ns. Each molecule’s deviation, fluctuation,
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and percentage of H-bond interactions were analyzed. The known drug Lorcaserin was found to
occupy the active pocket by maintaining a strong hydrogen bond with Asp 134 (97%). The receptor in
the presence of Lorcaserin was found to produce deviations between 2.75–6.3 Å until 25 ns, where the
deviation declined to 4.8 Å which continued until the end of the simulation (Figure 3a). The majority
of ligand deviations were observed between 2.4 to 3.2 Å and from 40ns, a steady pace in deviations
was observed till the end of simulations. The majority of amino acids fluctuated below 3.0 Å and a few
amino acids (31 and 160) fluctuated above 4.5 Å.Biomolecules 2019, 9, x FOR PEER REVIEW 10 of 19 
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Figure 3. The 5HT2C receptor and molecules complex deviation, fluctuations, and interaction percentage
at the end of simulation study: (a) Receptor—Lorcaserin; (b) Receptor—ZINC32123870.
At the end of simulations run, only three complexes were found to maintain the hydrogen bond
with the conserved amino acid of the receptor. ZINC32123870 molecule retained all interactions
produced in the docking studies. Along with them, two more pi–pi interactions were observed with Trp
324 and Phe 223 at the end of simulations. The salt bridge formed during the docking studies with
Asp134 vanished by the end of simulations (Figure 3b). The receptor made huge deviations, ranging
from 2.4 to 7.1 Å in complex with ZINC32123870. The inclinations in deviations were reported up to
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30 ns, reaching a maximum deviation of 7.1 Å. From there, deviations declined, ranging between 6.0
to 7.0 Å. In contrast, ligand deviations declined from 3.2 to 0.8 Å at the end of 10 ns and deviations
later increased, with the majority of them observed between 2.0 to 3.0 Å. With regard to amino acid
fluctuations during simulation, most of the amino acids were reported below 3.0 Å except for two
regions (one between 200–240 and the other in the tail-end region).
The receptor-ZINC40312983 complex generated only one H-bond with Asp 134 (99%) at the
end of simulations (Figure 4a). Major changes observed after simulation was conversion of salt
bridge between molecule and Asp 134 to hydrogen bond and all remaining interactions observed in
docking study were vanished after simulation. The RMSD graph of complex obtained at the end of
simulations reported that protein made huge deviations, inclinations, and declinations throughout the
simulation within a range of 3.5–9.0 Å. Concomitantly, ligand deviations during the simulation run
were observed to be high, ranging between 3.0 and 10.5 Å. In the complex state, both ligand and the
receptor maintained nearly the same pace of deviations graph throughout the simulations. The RMSF
graph reported that most of amino acids fluctuations were below 3.0 Å. Amino acids between 200–225
and around 325 fluctuated more during the simulation run and were reported above 3.0 Å.
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The ZINC32124535 molecule maintained similar interactions produced during docking studies
with Asp 134 even after simulation run completion (Figure 4b). Protein deviations were reported from
3.2 Å to a maximum of 7.2 Å and finally settled below 7.2 Å. Compared to protein, ligand maintained
steady state deviations between 2.4 to 3.2 Å throughout the simulations. The tail-end amino acids
fluctuated more during simulations and were reported above 3.0 Å, while the majority of amino acids
fluctuated below 3.0 Å. The receptor residues in the 200–225 range reported deviations above an
acceptable range (1–3 Å).
In all the 5HT2C receptor-ligand complexes, residues ranging 200–240 produced fluctuations and
were majorly loop regions. Generally, loop regions fluctuated more during simulations to attain a
stable conformational state. Deviations made by the receptor during the simulation runtime inform
us about the structural conformational changes undergone by residues in the protein for attaining a
stable confirmation. In all the four complexes, the 5HT2C receptor produced deviations throughout the
simulation run. The receptor and molecules also generated deviations. This confirms that molecule
conformational changes are proportional to protein conformational changes. Moreover, molecules
maintained their position inside the active pocket supported with strong interactions with residues in
the active pocket.
The major difference in binding modes observed at the end of simulations was mainly because
of the flexible nature adopted by the receptor and molecules during simulations. In general docking
studies, only the ligand is in flexible mode, while the receptor is in rigid mode. This major difference in
the flexibility natures maintained by the receptor and ligand during docking and simulation studies
plays a crucial role in generating interactions between the receptor and ligand. The flexibile nature
supports both the receptor and ligand in generating a higher number of conformational states and
thereby aids in the development of new hydrogen bonds or deduction of existing hydrogen bonds.
In the present study, at the end of simulation only three molecules, ZIN32123870, ZINC40312983
and ZINC32124535 were found to maintain a strong hydrogen bond interaction with the active site
amino acid Asp 134. After simulations, the other four molecules failed to conserve the interactions made
during the docking studies. The simulation analysis of three complexes confirm that the interactions
made by the molecules with the crucial residue of the receptor was conserved throughout simulation
time and the percentage of H-bond interaction between molecules and Asp134 was above 85%. These
results reinstate that the molecule was stable inside the active pocket with the same binding profile.
Receptor deviations in all the complexes were mainly due to flanking end regions. Counteracting these
deviations, ligands also showed certain deviations without losing the H-bond interactions or falling
out of the active pocket.
3.5. Cross Validation of the Hits
Molecular specificity against the target is more important to reduce adverse side effects. Specificity
plays a crucial role in screening agonists targeting the 5HT2C receptor because of the high sequence
similarity of the conserved domains, as well as the overall sequence identity among the family members
(55% with 5HT2A and 58% with 5HT2B receptors, respectively) [41]. The three best hits identified
against 5HT2C receptor, ZINC32123870, ZINC40312983, and ZINC32124535, were cross validated
against other members of the family, 5HT2A and 5HT2B receptors, using the same protocol along
with Lorcaserin.
3.5.1. 5HT2A Receptor
The 5HT2C receptor crystal structure (PDB ID: 6BQG) was chosen as a template for developing the
3D structure of 5HT2A receptor. The energy-based model was built and validated using Ramachandran
plot and Errat score. The Ramachandran plot summarized that the majority of amino acids were in
the allowed region (99.7%) with a few outliners (0.3%). However, the ERRAT score of the built model
showed an overall quality factor of 83.11, which revealed that the model needed refinement. The model
refinement was carried out using the Desmond module with default parameters. After refinement,
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the model was grouped into five clusters based on deviations and energy using a clustering method.
The best cluster center, based on the minimal deviations and energy was considered for further docking
and simulation studies.
Using the Sitemap module, the active pocket in the receptor was identified and the grid was
generated around the site through receptor grid generation application. The three hit molecules were
docked into this active site using Glide XP docking protocol and their interactions were analyzed.
None of the molecules produced interactions with the conserved residue at the end of docking study.
However, to further analyze the interaction profile, the three complexes were simulated. ZINC32124535
molecule was found to produce hydrogen bond interaction with conserved residue Asp 155 (60%),
whereas the other two molecules failed to produce hydrogen bonds with any one of the residues in
active pocket (Figure 5). After simulation, the PRIME energies were also calculated. ZINC32123870
molecule showed the highest energy, followed by ZINC32124535 and ZINC40312983 (Table 3).
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Table 3. Interactions of three potential hits along with known drug during the docking and simulation
studies along with PRIME energy calculations.
Molecule Receptor
Before MDS After MDS
Interactions
Profile
PRIME Energy
(Kcal/mol) Interactions
PRIME Energy
(Kcal/mol)
Lorcaserin
5HT2C
Asp134(1HB & 1SB)
Phe327(pi–pi) −41.27 Asp134(1HB) −43.72
5HT2B Asp135(1SB) −43.24 Asp135(1HB)Gln359(1SB) −42.04
5HT2A Ser 432 −32.48 −33.01
ZINC
32123870
5HT2C
Asp134(1HB & 1SB)
Phe327(pi–pi),
Phe328(pi–pi)
−58.30
Asp134(1HB)
Phe327(1HB)
Phe223(pi–pi)
Trp324(pi–pi)
Phe328(pi–pi)
−76.03
5HT2B
Asp135(1HB & 1SB)
Phe340(pi-cation) −62.85
Asp135(1HB &
1SB),Trp337(pi–pi) −64.20
5HT2A Ser 432(1HB) −44.62 No interactions −58.27
ZINC
40312983
5HT2C
Asp134(1SB)
Leu209(1HB)
Asn331(1HB)
−52.52
Asp134(1HB)
Tyr358(pi-cation)
Ser110(1HB)
−34.74
5HT2B
Asp135(1HB & 1SB)
Phe340(pi-cation) −62.56
Asp135(1HB & 1SB)
Phe214(pi-cation)
Phe341(pi–pi)
−63.55
5HT2A Lys 429(1HB) −48.20 Asp120(pi-cation) −31.12
ZINC
32124535
5HT2C
Asp134(1HB &
1SB) −49.66
Asp134
(1HB & 1SB) −70.54
5HT2B Asp135(1SB) −55.75 Phe226(pi–pi)Trp337(pi–pi) −70.24
5HT2A
Lys 429
(1HB&2pi-cation) −38.39
Asp155(1HB)
Thr134(1HB)
Lys 429(2pi-cation)
−41.34
3.5.2. 5HT2B Receptor
The receptor crystal structure was imported from protein databank (PDB ID: 4IB4) with a resolution
of 2.7 Å. All three hit molecules produced interactions with active pocket amino acids along with
the highly conserved amino acid Asp 135. Further, complexes were subjected to molecular dynamic
simulations to verify whether interactions were retained or lost after 50 ns run time. Except for the
5HT2B-ZINC32124535 complex, the remaining all complexes preserved interactions with the conserved
amino acid (Figure 6). The PRIME energy values after simulation were also listed. The ZINC32124535
molecule showed the highest energy, followed by ZINC32123870 and ZINC40312983 (Table 3).
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3.6. Homology Model vs. Crystal Structure
Until the crystal structure was made available, the majority of the screening of novel molecules
against he 5HT2C receptor were carried with homology models built using the bovin rhodopsin
nd GPCR’s (G protein-c upl d receptors) like human β2-a renergic G protein-c upl d rece tor.
The accuracy of the built mod l is considered very important for generating a potential hit against
the t rget. If it has flaws, it leads to the generation of false positiv s. He ce, there is also need
to revalidate the reported potential hits with the crystal structure. To elucidate th difference in the
docking and simulation studies with regard to the homology model and crystal structur s, this study
implemente the hom logy model vs. c ystal structure with the select d hits.
Ho ology modeling f 5HT2C was performed using a p ime homology modeling tool. The X-ray
crystal structure of 5HT2B receptor (PDB ID: 4NC3 with a resolution 2.8 Å) with 53.825% similarity
against query equenc was prefe red as a template for developing a 3D structure of the receptor.
The Ramach ndran plot for the built mod l reported 99.7% amino acids of the predi ed model
were in allowed regions and 0.3% we e in disallowed regions. Molecul r dynam c simulations were
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carried with the modeled 5HT2C receptor to further refine the built model for a time period of 50 ns.
The refined model Ramachandran plot reported 85.4% amino acids in the favorable region, 13.9%
in the additionally allowed region, and 0.6% in generously allowed regions, with no amino acids in
disallowed regions.
The crystal and modeled protein structures were superimposed to check major deviations between
their structures with regard to the active pocket. Two regions, namely 185–215 and 255–300 amino
acid residue stretches in built model, were loops, whereas the crystal structure had helices along
with a loop with regard to the 185–215 stretch, and the same 255–300 stretch replaced with BRIL [40]
was majorly in helix form (Figure 7a). The major modifications (185–215) made an influential impact
on the distances and bond angles of the amino acids (Figure 7b) in the active pocket, which was
clearly observed in docking studies of receptor (modeled and crystal structure) with the standard
drug lorcaserin (Figure 7c,d). The docking G score with the homology model was −4.66 while the
crystal structure exhibited a G score of −6.55. Molecular dynamic simulation studies showed one
hydrogen bond and salt bridge interaction with Asp 134 of both the homology modeled and crystal
structure 5HT2C receptor. The H-bond was shared between NH+ group (main moiety) of Lorcaserin
with C=O of Asp 134 residue of the receptor. In addition, only the crystal 5HT2C receptor- Lorcaserin
complex showed pi–pi interaction. The pi–pi interaction was observed between Phe 327 residue and
with 3-methylazepane ring (six-membered ring) of Lorcaserin.
Biomolecules 2019, 9, x FOR PEER REVIEW 16 of 19 
time perio  of 50 ns. The refined m del Ramachandran plot reported 85.4% amino acids in the 
favorable region, 13.9% in th  additionally allow d region, nd 0.6% in generously allowed regions, 
with no amino acids in disallowed regions. 
 crystal and modeled protein s ructur s wer  su erimp sed to check major deviations 
between their tructu s with regard o the a tive pocket. Two regions, namely 185–21  and 255–300 
mino acid residue stretches in built mod l, were loops, whereas the crystal structure had helices 
along with a loop with regard to the 185–215 stre ch, and the same 255–300 stretch replaced with 
BRIL [40] was majorly in helix form (Figure 7a). The major modifications (185–215) made an 
influential impact on the distances and bond angles of the amino acids (F gure 7b) in t e active 
pocket, which was clearly observed in docking studies of receptor (modeled and crys al structure) 
with the standard drug lorcaserin (Figure 7c,d). The docking G score with the homology model was 
−4.66 while the crystal structure exhibited a G score of −6.55. Mole ular dynamic simulati n studies 
showed one hydrogen bond and salt br dge interaction with Asp 134 of b th the h mology modeled 
and crystal structur  5HT2C r cept r. The H-bond was shared between NH+ group (main moiety) of 
Lorcaserin with C=O of Asp 134 residue of the recep or. In addition, only the crystal 5HT2C re eptor- 
Lorcas rin complex showed π–π interaction. The π–π interaction was obs rved betwe n Phe 327 
residue and with 3-methylazepan  ring (six-membered ring) of Lorcaserin. 
 
Figure 7. (a) Superimposition of homology model (blue colored) with crystal structure (PDB ID: 
6BQG; brown colored), major deviations were highlighted inside box. (b) Influential and important 
amino in active pocket of 5HT2C receptor; (c) LigPlot of 5HT2C (homology model) with the known 
drug Lorcaserin; (d) LigPlot of 5HT2C (crystal structure) with the known drug Lorcaserin. 
From the cross validation results, out of three hits, ZINC32124535 was found to be best 
potential hit against the 5HT2C receptor. Even though it showed interaction with the 5HT2A receptor 
conserved region, considering the percentage of hydrogen bond interactions against the conserved 
residue, the molecule was more specific toward the 5HT2C receptor. The other two hits also made 
interactions with conserved amino acid of two receptors (5HT2C and 5HT2B, respectively), with a 
Figure 7. (a) Superimposition of homology model (blue colored) with crystal structure (PDB ID: 6BQG;
brown colored), major deviations were highlighted inside box. (b) Influential and important amino
in active pocket of 5HT2C receptor; (c) LigPlot of 5HT2C (homology model) with the known drug
Lorcaserin; (d) LigPlot of 5HT2C (crystal structure) with the known drug Lorcaserin.
From the cross validation results, out of three hits, ZINC32124535 was found to be best potential
hit against the 5HT2C receptor. Even though it showed interaction with the 5HT2A receptor conserved
region, considering the percentage of hydrogen bond interactions against the conserved residue,
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the molecule was more specific toward the 5HT2C receptor. The other two hits also made interactions
with conserved amino acid of two receptors (5HT2C and 5HT2B, respectively), with a difference in
the hydrogen bond percentage. Comparing the known drug interaction among the three receptors,
the hydrogen bond interaction percentage after simulations studies specifies that the hit is more specific
to 5HT2C receptor. From these observations, all three molecules were concluded as the potential hits
against the 5HT2C receptor. Based on interaction percentages and cross validation results, out of
three hits, ZINC32124535 was found to be best potential hit against the 5HT2C receptor, followed by
ZINC40312983 and ZINC32123870.
4. Conclusions
Obesity has become a life-threatening multifactorial global pandemic. Its economic burden
compels us to look for more effective measures, as current measures such as lifestyle modifications,
bariatric surgery or medications/supplements available in market are not sufficient to control the
disease. Therefore, there is a need to develop new drugs for the treatment of obesity. Among the targets
reported so far, the 5HT2C receptor has gained increased attention and is also a challenging target
because of high sequence similarity of other receptors within the group. This study mainly focused
on elucidating the specificity of screened molecules among 5HT2A, 5HT2B, and 5HT2C receptors.
Overall, the present computational study reported three molecules, ZINC40312983, ZINC32123870,
and ZINC32124535, to be the best agonists for the 5HT2C receptor compared to other members in
this subtype. ZINC32124535 was identified as the best potential hit and needs further in vitro and
in vivo validations.
Supplementary Materials: The following are available online at http://www.mdpi.com/2218-273X/9/10/556/s1,
Figure S1: Interaction profile of known drug lorcaserin with 5HT2C receptor after docking studies depicted in both
3D (left side; Hydrogen bonds (yellow), salt bridge (magenta) and pi–pi (green) interactions as shown in dotted
lines) and 2D (right side) forms.
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